Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma

Isidro Machado, José Antonio López Guerrero, Samuel Navarro, Empar Mayordomo, Katia Scotlandi, Piero Picci, Antonio Llombart-Bosch

Research output: Contribution to journalArticle

Abstract

Galectin-1 (GAL-1) is frequently expressed in osteosarcomas. Although a valuable diagnostic marker to differentiate between chondroblastic osteosarcomas and conventional chondrosarcomas, it has not been tested in the Ewing sarcoma family of tumors (ESFTs). We studied by immunohistochemistry GAL-1 expression in 43 osteosarcomas, 23 chondrosarcomas, and 217 genetically confirmed ESFTs using a tissue microarray. GAL-1 was expressed in 78 % of osteosarcomas, 33 % of chondrosarcomas, and 8 % of ESFTs. Osteoblastic and small cell osteosarcoma subtypes expressed GAL-1 in a high percentage of cells when compared with the other histological subtypes, whereas two chondroblastic osteosarcomas were negative. GAL-1 was mainly expressed in high-grade chondrosarcomas (grade III). ESFTs were rarely positive (8 %), and this was not related to the histological subtype nor to the clinical outcome. Although GAL-1 expression distinguishes chondroblastic osteosarcomas from conventional chondrosarcomas and is usually negative in conventional chondrosarcomas, the final diagnosis needs to incorporate histopathology since some chondroblastic osteosarcomas fail to express GAL-1, while high-grade chondrosarcomas are GAL-1 positive. Since GAL-1 is frequently expressed in osteogenic tumors, including small cell osteosarcoma, but rarely positive in ESFTs, its expression seems a valuable tool for distinguishing between these lesions. GAL-1 immunoexpression is not indicative of prognosis in ESFT.

Original languageEnglish
Pages (from-to)665-671
Number of pages7
JournalVirchows Archiv
Volume462
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Small Cell Sarcoma
Galectin 1
Ewing's Sarcoma
Osteosarcoma
Chondrosarcoma
Neoplasms

Keywords

  • Chondrosarcoma
  • ESFT
  • GAL-1
  • Immunohistochemistry
  • Osteosarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Machado, I., López Guerrero, J. A., Navarro, S., Mayordomo, E., Scotlandi, K., Picci, P., & Llombart-Bosch, A. (2013). Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. Virchows Archiv, 462(6), 665-671. https://doi.org/10.1007/s00428-013-1423-3

Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. / Machado, Isidro; López Guerrero, José Antonio; Navarro, Samuel; Mayordomo, Empar; Scotlandi, Katia; Picci, Piero; Llombart-Bosch, Antonio.

In: Virchows Archiv, Vol. 462, No. 6, 06.2013, p. 665-671.

Research output: Contribution to journalArticle

Machado, I, López Guerrero, JA, Navarro, S, Mayordomo, E, Scotlandi, K, Picci, P & Llombart-Bosch, A 2013, 'Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma', Virchows Archiv, vol. 462, no. 6, pp. 665-671. https://doi.org/10.1007/s00428-013-1423-3
Machado, Isidro ; López Guerrero, José Antonio ; Navarro, Samuel ; Mayordomo, Empar ; Scotlandi, Katia ; Picci, Piero ; Llombart-Bosch, Antonio. / Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. In: Virchows Archiv. 2013 ; Vol. 462, No. 6. pp. 665-671.
@article{2adf65b931f045f3bea9a2d0b004f9b4,
title = "Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma",
abstract = "Galectin-1 (GAL-1) is frequently expressed in osteosarcomas. Although a valuable diagnostic marker to differentiate between chondroblastic osteosarcomas and conventional chondrosarcomas, it has not been tested in the Ewing sarcoma family of tumors (ESFTs). We studied by immunohistochemistry GAL-1 expression in 43 osteosarcomas, 23 chondrosarcomas, and 217 genetically confirmed ESFTs using a tissue microarray. GAL-1 was expressed in 78 {\%} of osteosarcomas, 33 {\%} of chondrosarcomas, and 8 {\%} of ESFTs. Osteoblastic and small cell osteosarcoma subtypes expressed GAL-1 in a high percentage of cells when compared with the other histological subtypes, whereas two chondroblastic osteosarcomas were negative. GAL-1 was mainly expressed in high-grade chondrosarcomas (grade III). ESFTs were rarely positive (8 {\%}), and this was not related to the histological subtype nor to the clinical outcome. Although GAL-1 expression distinguishes chondroblastic osteosarcomas from conventional chondrosarcomas and is usually negative in conventional chondrosarcomas, the final diagnosis needs to incorporate histopathology since some chondroblastic osteosarcomas fail to express GAL-1, while high-grade chondrosarcomas are GAL-1 positive. Since GAL-1 is frequently expressed in osteogenic tumors, including small cell osteosarcoma, but rarely positive in ESFTs, its expression seems a valuable tool for distinguishing between these lesions. GAL-1 immunoexpression is not indicative of prognosis in ESFT.",
keywords = "Chondrosarcoma, ESFT, GAL-1, Immunohistochemistry, Osteosarcoma",
author = "Isidro Machado and {L{\'o}pez Guerrero}, {Jos{\'e} Antonio} and Samuel Navarro and Empar Mayordomo and Katia Scotlandi and Piero Picci and Antonio Llombart-Bosch",
year = "2013",
month = "6",
doi = "10.1007/s00428-013-1423-3",
language = "English",
volume = "462",
pages = "665--671",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma

AU - Machado, Isidro

AU - López Guerrero, José Antonio

AU - Navarro, Samuel

AU - Mayordomo, Empar

AU - Scotlandi, Katia

AU - Picci, Piero

AU - Llombart-Bosch, Antonio

PY - 2013/6

Y1 - 2013/6

N2 - Galectin-1 (GAL-1) is frequently expressed in osteosarcomas. Although a valuable diagnostic marker to differentiate between chondroblastic osteosarcomas and conventional chondrosarcomas, it has not been tested in the Ewing sarcoma family of tumors (ESFTs). We studied by immunohistochemistry GAL-1 expression in 43 osteosarcomas, 23 chondrosarcomas, and 217 genetically confirmed ESFTs using a tissue microarray. GAL-1 was expressed in 78 % of osteosarcomas, 33 % of chondrosarcomas, and 8 % of ESFTs. Osteoblastic and small cell osteosarcoma subtypes expressed GAL-1 in a high percentage of cells when compared with the other histological subtypes, whereas two chondroblastic osteosarcomas were negative. GAL-1 was mainly expressed in high-grade chondrosarcomas (grade III). ESFTs were rarely positive (8 %), and this was not related to the histological subtype nor to the clinical outcome. Although GAL-1 expression distinguishes chondroblastic osteosarcomas from conventional chondrosarcomas and is usually negative in conventional chondrosarcomas, the final diagnosis needs to incorporate histopathology since some chondroblastic osteosarcomas fail to express GAL-1, while high-grade chondrosarcomas are GAL-1 positive. Since GAL-1 is frequently expressed in osteogenic tumors, including small cell osteosarcoma, but rarely positive in ESFTs, its expression seems a valuable tool for distinguishing between these lesions. GAL-1 immunoexpression is not indicative of prognosis in ESFT.

AB - Galectin-1 (GAL-1) is frequently expressed in osteosarcomas. Although a valuable diagnostic marker to differentiate between chondroblastic osteosarcomas and conventional chondrosarcomas, it has not been tested in the Ewing sarcoma family of tumors (ESFTs). We studied by immunohistochemistry GAL-1 expression in 43 osteosarcomas, 23 chondrosarcomas, and 217 genetically confirmed ESFTs using a tissue microarray. GAL-1 was expressed in 78 % of osteosarcomas, 33 % of chondrosarcomas, and 8 % of ESFTs. Osteoblastic and small cell osteosarcoma subtypes expressed GAL-1 in a high percentage of cells when compared with the other histological subtypes, whereas two chondroblastic osteosarcomas were negative. GAL-1 was mainly expressed in high-grade chondrosarcomas (grade III). ESFTs were rarely positive (8 %), and this was not related to the histological subtype nor to the clinical outcome. Although GAL-1 expression distinguishes chondroblastic osteosarcomas from conventional chondrosarcomas and is usually negative in conventional chondrosarcomas, the final diagnosis needs to incorporate histopathology since some chondroblastic osteosarcomas fail to express GAL-1, while high-grade chondrosarcomas are GAL-1 positive. Since GAL-1 is frequently expressed in osteogenic tumors, including small cell osteosarcoma, but rarely positive in ESFTs, its expression seems a valuable tool for distinguishing between these lesions. GAL-1 immunoexpression is not indicative of prognosis in ESFT.

KW - Chondrosarcoma

KW - ESFT

KW - GAL-1

KW - Immunohistochemistry

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84878942435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878942435&partnerID=8YFLogxK

U2 - 10.1007/s00428-013-1423-3

DO - 10.1007/s00428-013-1423-3

M3 - Article

C2 - 23681112

AN - SCOPUS:84878942435

VL - 462

SP - 665

EP - 671

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

IS - 6

ER -